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reasonable representation of the selected actual rates. Mortality rates were stratified 
by age. A probabilistic sensitivity analysis (PSA) was performed to account for the 
effect of uncertainty in the model parameters. Results: For the current practice, 
we estimated that annually 75% of CDI cases are new infections; the rest are recur-
rences; 40% of CDI occurs among individuals aged 80+, 41% among 60-79, and 19% 
among those below 60; hospital-based CDI accounted for 69 % of all CDI, while 
community and LTCF based CDI accounted for 26% and 5% of all CDI, respectively. 
The recurrence rates for current antibiotic treatment were estimated at 25.3% and 
35.9% for first and second recurrences, respectively. The recurrence rate for FMT 
was estimated at 10.4%. For the base case, we estimated 79.0 and 64.9 per 100,000 
population cases of CDI for current practice and FMT, respectively. The number of 
deaths is estimated at 5.8 and 4.7 per 100,000 population for current practice and 
FMT, respectively. The results of the cost-effectiveness analysis indicate that in the 
base case, FMT is a dominant strategy. The results of the PSA reveal that for the 
majority of simulations, FMT is dominant (positive incremental QALYs and negative 
incremental cost). ConClusions: The results of the cost-effectiveness analysis 
indicate that FMT appears to be the dominant strategy, with lower costs and better 
outcomes than the existing antibiotic treatments.
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objeCtives: To demonstrate the role of sensitivity analysis (SA) in assessing clinical 
and economic impact of national immunization programs. Methods: We applied 
our recent cost-effectiveness model of pneumococcal vaccination to the local data 
in Slovenia, which is particularly notable for high incidence of community-acquired 
pneumonia (CAP) and acute otitis media (AOM). In the model, we followed the cohort 
of 21,938 Slovenian infants over their lifetime and compared two pneumococcal vac-
cine (PCV) options (PHiD-CV and PCV-13) with each other and with a “no vaccination” 
strategy (NVS) from a payer perspective, both at current and parity prices. The model 
simulated vaccine protection against both pneumococcal diseases (invasive, CAP, 
AOM) and AOM related to non-typeable Heamophilus influenzae (NTHi). We performed 
various sensitivity analyses, including probabilistic Monte Carlo simulations by 
employing parameter values derived from clinical trials and post-marketing surveil-
lance data. Results: SA has shown that PHiD-CV vaccine dominated PCV-13 vaccine 
across the range of parameters, both at current and parity prices, and robustness 
of domination was further confirmed by more than 95% out of 1,000 Monte Carlo 
simulations, where PHiD-CV dominated PCV-13. SA when comparing each vaccine 
with NVS showed that at current prices reduction of CAP, AOM, and myringotomy-
procedure incidence by 50% in children younger than 10 years increased incremental 
cost-effectiveness ratio (ICER) from € 4,237 per quality-adjusted life year (QALY) to 
€ 18,917/QALY for PHiD-CV and from € 16,049/QALY to € 35,040/QALY for PCV-13. At 
current prices, vaccination with PHiD-CV dominated NVS when at least 17.5% of 
parents of sick children would take a paid leave, which – in the Slovenian jurisdiction 
– constitute direct costs; in comparison, corresponding ICER for vaccination with PCV-
13 vs. NVS was € 12,306/QALY. ConClusions: Both base case and SA model findings 
suggest that Slovenian authorities would save resources by implementing national 
immunization program of infants with PHiD-CV as a vaccine of choice.
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objeCtives: This study assesses the PAN-genotypic costs-effectiveness of sofos-
buvir compared with standard of care in the Netherlands. Methods: Untreated 
hepatitis C virus (HCV) infection results in chronic liver disease. The prevalence in 
The Netherlands is estimated at 0.1-0.4% with 50% of patients having HCV genotype 
1 (GT1), 10% GT2, 30% GT3 and 10% GT4-5-6. Current standard of care (SoC), regardless 
of genotype consists of weekly subcutaneous pegylated interferon-alpha (PegIFN-α ) 
plus daily oral ribavirin. In GT1, the protease inhibitors telaprevir or boceprevir 
are added. Sofosbuvir (SOF), a novel Direct Antiviral Agent (DAA), has consistently 
demonstrated high rates of sustained virological response (SVR) when given with 
ribavirin±PegIFN-α . This cost-effectiveness evaluation is based on a Markov transi-
tion model, that combines efficacy and safety data from published RCTs with SOF 
and SoC in all genotypes with specific attention for subgroups for whom no alterna-
tives are available (no PegIFN-α eligibility). Medical resource use is based on clinical 
guidelines and expert opinion. Costs include treatment costs, monitoring costs, costs 
for treatment of complications and adverse events as well as productivity loss. The 
model has a lifetime horizon and costs are discounted with 4% and outcomes with 
1.5%. Results are presented for an HCV mono-infected population with 20% cirrhotic 
patients. Results: The incremental QALY gain for SOF was 1.23 in PegIFN-α eligible 
patients and 2.68 in those not eligible for PegIFN-α . The incremental costs were € 25,291 
for PegIFN-α eligible patients and € 89,707 for those not eligible for PegIFN-α . The result-
ing PAN-genotypic ICERs were € 20,487 for PegIFN-α eligible patients and € 33,516 for 
those not eligible for PegIFN-α . ConClusions: PAN-genotypic cost-effectiveness is 
demonstrated for sofosbuvir in the treatment of HCV in the Netherlands.
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were however not considered to be able to replace CE except for MEA (14% reported 
that it could replace CE versus 0% for the others). In countries where CE is not 
formally used, the proportion of experts considering them as relevant was lower 
except for the BOM: RoI (46%), MCDA (46%), QoC (18%), BOM (60%) and MEA (33%). 
Most reported barriers for use of the alternative methods were: no political interest, 
unfamiliarity with these methodologies, and lack of robust input data to conduct 
the evaluation. The method selection was most influenced by the appropriate-
ness to the decision-making question, the country, and the vaccine or disease type 
assessed. ConClusions: Creating awareness on additional economic evaluation 
methods may support and facilitate the vaccine reimbursement decision-making 
process in Europe alongside the current CE analysis.
PIN69
allocaTINg vaccINe fuNdS for PNeumococcal vaccINaTIoN of 
INfaNTS aNd older adulTS: a meThod for STraTegIc evaluaTIoN IN 
The NeTherlaNdS
Delgleize E., Standaert B.
GlaxoSmithKline Vaccines, Wavre, Belgium
objeCtives: Pneumococcal conjugate vaccines are available in the Netherlands 
against pneumococcal disease in infants and adults. This analysis aimed to identify 
an optimal vaccination strategy between infants and adults when the budget is 
constrained. Extensive sensitivity analysis is performed around herd protection on 
Invasive Pneumococcal Disease (IPD) and Community Acquired Pneumonia (CAP) 
resulting from infant vaccination. Methods: We developed an optimization model 
linked to a prevalence-based disease management sub-model. This program allows 
finding an optimal solution given an objective function (minimize cases; minimize 
quality-adjusted life-years (QALYs) lost; minimize life-years (LYs) lost) under budget 
constraints. Vaccine efficacy (VE) is based on clinical trial data. The model is run for 
different scenarios seeking for minimum indirect effect on IPD and on CAP in the 
whole population needed to keep infant vaccination as the optimal intervention, 
given a constrained budget. Results: With the current disease burden and vaccine 
coverage rate in the Netherlands and considering an overall VE in adults against 
CAP of 4.5% and against IPD of 37% (estimates based on CAPITA clinical trial results), 
the model shows that vaccinating infants is the optimal strategy that minimizes 
pneumococcal-related events when compared with adult vaccination. If the objec-
tive is to minimize QALYs lost, vaccinating infants remains the optimal selection 
as long as the net indirect effect is ≥ 2% on CAP or ≥ 3% on IPD. When the objective 
is to minimize LYs lost, the minimum indirect effect should be ≥ 3% on CAP or ≥ 7% 
on IPD. Sensitivity analyses show that even if CAP VE in adults is 3 times higher, the 
estimated minimum indirect effect needed is still below the one obtained with the 
first pneumococcal conjugate vaccine. ConClusions: The optimal strategy within 
a constrained budget is to maintain infant vaccination instead of initiating elderly 
vaccination, given the reported evidence of indirect protection.
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objeCtives: A live-attenuated vaccine aimed at preventing herpes zoster (HZ) and 
post-herpetic neuralgia (PHN) is available in Europe for immunocompetent adults 
aged ≥ 50 years. The study objective is to assess the incremental cost-effectiveness 
ratio (ICER) of a vaccination program for this population in Spain when compared 
against the current strategy of no-vaccination. Methods: A state-transition 
Markov model has been developed to simulate the natural history of HZ and PHN 
and the lifetime effects of vaccination. Several health states are defined including 
good health, HZ, PHN and death. HZ and PHN health states are divided to reflect 
pain severity. The Markov cycle was 1 month and lifetime horizon. The HZ vaccine 
lifetime duration (waning rate of 8.3%) and a PHN vaccine duration of 10 years. PHN 
proportion was obtained from Cebrián-Cuenca (2011) and adjusted to reflect the 
incidence of PHN among HZ patients with pain. The vaccine coverage rate estimated 
was 30%, considering discount rates of 3% for costs and utilities. The strength of the 
results was confirmed with a probabilistic analysis based on Monte Carlo simula-
tion. Results: A vaccination strategy compared to a no-vaccination resulted in 
12.659€ /QALY and 11.926€ /QALY under third-party payer perspective and societal 
perspective respectively for the population aged ≥ 50 years. ICERs were within the 
commonly accepted thresholds of 30.000£/QALY (36.000€ /QALY) gained in the UK. 
Sensitivity analyses showed that the model was most sensitive to discount rates 
and duration of vaccine protection. The lowest ICER was observed for the 70-74 years 
age group (6.657€ /QALY under third-party payer perspective). ConClusions: In 
Spain, a shingles vaccination strategy in older population would be a cost-effective 
alternative in comparison with no vaccination, due to an ICER of 12.659€ /QALY from 
the third-party payer perspective.
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objeCtives: To estimate the cost-effectiveness of Fecal Microbiota Transplant 
(FMT) for Clostridium difficile infection (CDI) as compared to the current practice 
comprising of antibiotic treatments. Methods: We developed a decision analytic 
model to compare strategies for the management of CDI, by age, gender, and three 
sources of infection: hospitals, communities, and long-term care facilities (LTCF). We 
performed validation analyses to demonstrate that the predicted CDI rates were a 
